|
|
Volumn 8, Issue 9, 2009, Pages 683-684
|
|
Difining innovation
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GLEVEEC;
IMATINIB;
UNCLASSIFIED DRUG;
ADVISORY COMMITTEE;
ARTICLE;
CANCER SURVIVAL;
CLINICAL STUDY;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
GOVERNMENT;
HEALTH CARE DELIVERY;
INNOVATION PASS PROGRAM;
MEDICAL TECHNOLOGY;
MYELOID LEUKEMIA;
NATIONAL HEALTH ORGANIZATION;
PRIORITY JOURNAL;
PROCESS DEVELOPMENT;
PROGRAM DEVELOPMENT;
QUALITY OF LIFE;
SOCIOECONOMICS;
TREATMENT RESPONSE;
UNITED KINGDOM;
COST BENEFIT ANALYSIS;
ECONOMICS;
HUMAN;
MASS COMMUNICATION;
MEDICAL RESEARCH;
NOTE;
PHARMACOLOGY;
BIOMEDICAL RESEARCH;
COST-BENEFIT ANALYSIS;
DIFFUSION OF INNOVATION;
DRUG INDUSTRY;
GREAT BRITAIN;
HUMANS;
PHARMACOLOGY;
|
|
EID: 69949132512
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2993 Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|